New clinical data from Caribou Biosciences underscores significant progress for its pipeline of CRISPR-based cell therapies. Recent Phase 1 trial results for two key candidates, vispa-cel and CB-011, highlight their therapeutic potential in treating aggressive cancers and set the stage for pivotal registration studies.
Compelling Efficacy in Lymphoma Treatment
Data from the ANTLER trial for vispa-cel (CB-010), presented on February 5, demonstrated strong efficacy in patients with large B-cell lymphoma. Within a subset of patients who received a product meeting an optimized profile, the therapy achieved an overall response rate of 86%, with a complete remission rate of 63%.
Investigators noted that factors such as HLA matching
Durable Response in Multiple Myelom
Separately, the company detailed results from the CaMMouflage study for CB-011 this past Saturday. This allogeneic CAR-T cell therapy targets multiple myeloma. The clinical data correlate CAR-T cell expansion directly with response durability and confirm the selected dosing regimen.
A dose of 450 million CAR-T cells has been selected for the upcoming expansion phase of the trial. One patient in the study has maintained a stringent complete remission for over 21 months, with no measurable residual disease detected. These findings support the view that the chosen lymphodepletion procedure facilitates optimal cell engraftment.
Institutional Ownership Reflects Confidence
The scientific interest in Caribou’s platform is mirrored in its shareholder base. Institutional investors and hedge funds currently hold approximately 77.51% of the company’s outstanding shares. Prominent firms like Millennium Management and the Aberdeen Group have adjusted their positions in recent quarters. Analysts from firms such as Truist Financial are already focusing on the long-term revenue potential linked to the transition into late-stage clinical testing.
The roadmap for the current calendar year is now established. The initiation of a crucial Phase 2 study for vispa-cel and the ongoing dose expansion for CB-011 represent the next key operational milestones. The validation of the Cas12a technology in the clinical setting will be a major factor in determining the future market positioning of Caribou’s off-the-shelf therapies.
Fact Summary
| Category | Details |
|---|---|
| Event | 2026 Tandem Meetings (ASTCT & CIBMTR) |
| Clinical Candidates | Vispa-cel (CB-010) and CB-011 |
| Key Metric | 86% Overall Response Rate (vispa-cel optimized) |
| Institutional Ownership | 77.51% |
| Last Update | February 7, 2026 |
| Next Step | Planned Pivotal Study for vispa-cel |
Ad
Caribou Biosciences Stock: Buy or Sell?! New Caribou Biosciences Analysis from February 8 delivers the answer:
The latest Caribou Biosciences figures speak for themselves: Urgent action needed for Caribou Biosciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.
Caribou Biosciences: Buy or sell? Read more here...
